Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03226301 |
|---|---|
| Brief Title: | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations |
| First Submitted : | May 15, 2017 |
| First Submitted that Met QC Criteria : | July 20, 2017 |
| First Posted : | July 21, 2017 |
| Last Update Submitted that Met QC Criteria : | August 3, 2020 |
| Last Update Posted : | August 4, 2020 |